Ge. Hanks et al., Survival advantage for prostate cancer patients treated with high-dose three-dimensional conformal radiotherapy, CA J SCI AM, 5(3), 1999, pp. 152-158
PURPOSE
The value of treating prostate cancer has been questioned, and some insist
that a survival benefit is demonstrated to justify treatment.
Prospective dose-escalation studies with three-dimensional conformal radiot
herapy technique have demonstrated improvement in biochemical freedom from
disease and local control. We report the outcomes of high-dose treatment wi
th three-dimensional conformal radiotherapy compared with low-dose treatmen
t for biochemical freedom from disease, freedom from distant metastasis, ca
use-specific survival, and overall survival.
PATIENTS AND METHODS
The study design was retrospective, involving pairs matched on independent
prognostic variables in which each patient treated with low-dose radiothera
py was matched with a patient treated with high-dose radiotherapy. Outcomes
were compared for two groups of patients:
Group I: Three-dimensional conformal radiotherapy treatment-296 patients tr
eated with more than 74 Gy matched on stage, grade, and prostate-specific a
ntigen level, to 296 patients treated with less than 74 Gy.
Group II: Three-dimensional conformal radiotherapy treatment-357 patients t
reated with more than 74 Gy matched on stage and grade to 357 patients trea
ted with less than 74 Gy.
RESULTS
Univariate analysis showed that dose is a significant predictor of biochemi
cal freedom from disease, freedom from distant metastasis, and cause-specif
ic survival for group I and biochemical freedom from disease, freedom from
distant metastasis, cause-specific survival, and overall survival for group
II. Multivariate analysis showed that dose is a significant independent pr
edictor in group I for biochemical freedom from disease and freedom from di
stant metastasis and for biochemical freedom from disease, freedom from dis
tant metastasis, cause-specific survival, and overall survival in group II.
DISCUSSION
These data provide strong support for the definitive treatment of prostate
cancer with high-dose (> 74 Gy) three-dimensional conformal radiotherapy Th
ese doses can be safely delivered with three-dimensional conformal radiothe
rapy techniques.
Various institutions and industry must collaborate to expand the technology
allowing the use of high-dose three-dimensional conformal radiotherapy in
the national practice beyond centers of technological excellence.